2 transcripts
SLRN
Earnings call transcript
NASDAQ
2024 Q2
13 Aug 24
in DLQI, were seen -- observed versus placebo at week 12 and also at week 16. The safety findings of izokibep were consistent with those observed
SLRN
Earnings call transcript
NASDAQ
2023 Q2
14 Aug 23
to the market in monoclonal antibodies against this target and without the introduction of new safety liabilities. We are pursuing late-stage development
- Prev
- 1
- Next